NeoGenomics (NASDAQ:NEO) A Key Player in NASDAQ 100 Top Stocks

May 14, 2025 01:54 AM PDT | By Team Kalkine Media

Google News:

NeoGenomics (NASDAQ:NEO) A Key Player in NASDAQ 100 Top Stocks — Image source: Shutterstock

Recent News

Oil States International (NYSE:OIS) Sees Turnaround in Profitability R...

Stevanato Group (NYSE:STVN) Balances Debt Use and Growth Strategy NYSE...

CME Group (NASDAQ:CME) Sees Stake Amid Market Nasdaq Composite

Halliburton (NYSE:HAL) Sees Activity Amid and Market NYSE Composite

Highlights

Institutional adjustments lead to changes in NeoGenomics stock holdings.

Company stock shows fluctuations and financial challenges despite revenue increase.

Insider activity reflects confidence in NeoGenomics' future trajectory.

NeoGenomics (NASDAQ:NEO) is a prominent company in the healthcare sector, specializing in cancer diagnostic testing services. Operating in both the U.S. and U.K., it provides clinical and advanced diagnostic solutions to healthcare providers around the globe. As part of its listing on NASDAQ, NeoGenomics plays a significant role in the biotechnology and diagnostic testing fields, contributing to the strength and innovation within the NASDAQ 100 Top Stocks.

Institutional Activity in NeoGenomics

Recent institutional adjustments reveal significant changes in how major financial players view NeoGenomics. Several firms, including The Manufacturers Life Insurance Company, made adjustments by reducing their stock holdings. Despite these reductions, a large portion of the company’s shares remains under institutional control. The combined stake held by institutional players in NeoGenomics continues to account for a dominant percentage, underscoring their continued interest in the company.

Stock Performance and Financial Metrics

NeoGenomics' stock has experienced notable fluctuations, showing a consistent pattern of performance over recent months. The company’s stock has been trading within a specific range, marked by a low and high point within the past year. While the company reported an increase in revenue, challenges remain as it continues to face financial pressures, reflected in negative returns on equity.

Changes in Ratings

Recent activity has shown both analysts and insiders adjusting their positions regarding NeoGenomics. Well-known firms have altered their outlook on the company, though no specific shifts have been dramatic. Meanwhile, several insiders have made notable moves.

About NeoGenomics

NeoGenomics (NASDAQ:NEO) remains an essential player in the oncology diagnostic services market, providing crucial support to healthcare professionals. Its dual focus on clinical services and advanced diagnostics continues to shape its role within medical research. The company’s significant presence in the diagnostic space makes it a notable entity within the healthcare sector.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.